Eli Lilly targets alleged black market sales of its experimental GLP-1 drug
Eli Lilly is suing six entities that it alleges are selling black market versions of its experimental weight-loss drug retatrutide. Lilly's lawsuits target U.S. entities selling illegal retatrutide products, including compounding pharmacies, medical spas and online sellers that sell retatrutide as a weight-loss "hack." Those entities falsely claim their drugs are for “research-use only” when...
We haven't written up this one. The Hill has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
